Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml.

European urology - 1 Jun 2014

Nordström Tobias, Aly Markus, Eklund Martin, Egevad Lars, Grönberg Henrik

Abstract excerpt

BACKGROUND: The diagnostic performance of a genetic score based on single nucleotide polymorphisms (SNPs) is unknown in the prostate-specific antigen (PSA) range of 1-3 ng/ml. A substantial proportion of men in this PSA span have prostate cancer (PCa), but biomarkers to determine who should undergo a prostate biopsy are lacking. OBJECTIVE: To evaluate whether a genetic risk score identifies men in the PSA range...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Endoscopic Ultrasound-Guided Fine Needle Aspiration

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Testing

Share to Neoplasm Grading

Share to Polymorphism, Single Nucleotide

Share to Prostate-Specific Antigen

Share to Prostatic Neoplasms

Share to Risk Assessment

Source

Identifiers

PMID: 23891454
DOI: 10.1016/j.eururo.2013.07.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml.PMID 23891454Read ↗

Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.Semantic proximity Read ↗

Personalized prostate cancer screening: improving PSA tests with genomic information.Semantic proximity Read ↗

Does genotyping of risk-associated single nucleotide polymorphisms improve patient selection for prostate biopsy when combined with a prostate cancer risk calculator?Semantic proximity Read ↗

Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study.Semantic proximity Read ↗

Assessment of a Polygenic Risk Score in Screening for Prostate CancerSemantic proximity Read ↗

Utility of incorporating genetic variants for the early detection of prostate cancer.Semantic proximity Read ↗

Prediction of prostate cancer from prostate biopsy in Chinese men using a genetic score derived from 24 prostate cancer risk-associated SNPs.Semantic proximity Read ↗

Prostate genetic score (PGS-33) is independently associated with risk of prostate cancer in the PLCO trial.Semantic proximity Read ↗

Clinical validity and utility of genetic risk scores in prostate cancer.Semantic proximity Read ↗

A genetic-based approach to personalized prostate cancer screening and treatment.Semantic proximity Read ↗

Clinical consequences of a genetic predisposition toward higher benign prostate-specific antigen levels.Semantic proximity Read ↗

Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.